CLEVELAND, May 17 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(BostonStockExchange:CFB), today announced that the Company is scheduled to present at the 2007 Robins Emerging Opportunities Conference to be held at The University Club in New York City, May 24.

Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, will give a presentation on the Company followed by a question and answer session on May 24, at 11:30 a.m. EDT. The presentation will be broadcast live over the Internet and archived for three months. Interested parties may tune in to the live presentation by visiting the Company's website at:

Cleveland BioLabs currently has two lead compounds in late stages of development. Curaxin CBLC102 is an orally administered small molecule designed to kill tumor cells by simultaneously targeting two key regulators of apoptosis. The Company has an ongoing Phase II trial with CBLC102 in hormone refractory prostate cancer.

The Company's other lead compound, Protectan CBLB502, is a modified protein of a microbe that protects cells from regulated cell death. CBLB502 is the first compound of its kind to provide protection from both gastrointestinal and hematopoietic (bone marrow/blood production) radiation- induced damage. CBLB502 is being developed initially as a radiation antidote for the military, rescue workers, nuclear plant personnel and eventually for all people who may be subject or vulnerable to nuclear attack or accident. Other applications for this technology include protection from cancer treatment side effects.

The Company recently submitted CBLB502 to the Department of Defense in response to a Request for Proposal (RFP) for medical radiation countermeasures to treat gastrointestinal effects of acute radiation syndrome. The RFP award would provide funding for development of the countermeasure through FDA approval, as well as a commitment to purchase up to 500,000 doses, thereafter.

Cleveland BioLabs management will be available for meetings with investors on May 23 and 24 in New York.

About The Robins Group

The Robins Group was created to provide professional investors with high quality research and brokerage services on under-followed small- and micro-cap equities. We prefer well-managed companies that dominate their particular niches through superior service, products and technology. Our research team employs fundamental analysis to arrive at a measure of value. Earnings power, cash flow, revenue growth, book value and financial strength are among the factors evaluated to determine investment potential.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in our Registration Statement on Form SB-2/A filed with the Securities and Exchange Commission on September 8, 2006.

    The Global Consulting Group
    Rachel Levine
    T: (646) 284-9439